Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Trogarzonon Dec 14, 2022 7:53am
131 Views
Post# 35170267

RE:RE:RE:RE:RE:RE:Great opportunity!

RE:RE:RE:RE:RE:RE:Great opportunity!The only guy who could have put this plan together was the former CEO Luc... he's gone thanks to this board.  We now have a CEO that has a tought time living without what is called a cheif of staff..ok.  We now have a new reality that almost excludes R&D after repositioning the company from specialty pharma to an R&D shop and then to an hybryd model and to now to specialty pharma once again....ok.  This new CEO will find no joy in such an environment and leave maybe to pursue new ventures. maybe.  The CMO's cancer dream will be dismantled and he also will have no joy in his life maybe..ok.  The CFO will need to find ways to cut, cut, cut and find new money.  Whit no R&D hope they can forget another OO even if they wanted to maybe. who will buy into another round of financing..ok.  All in all just sell the company and save yourself the trouble.  Anyway come the next AGM in less than 6 months how will you survive this... ok.
<< Previous
Bullboard Posts
Next >>